CN107771084A - 非晶金属‑有机框架 - Google Patents

非晶金属‑有机框架 Download PDF

Info

Publication number
CN107771084A
CN107771084A CN201680035888.XA CN201680035888A CN107771084A CN 107771084 A CN107771084 A CN 107771084A CN 201680035888 A CN201680035888 A CN 201680035888A CN 107771084 A CN107771084 A CN 107771084A
Authority
CN
China
Prior art keywords
organic framework
metal
amorphous metal
organic
amorphous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680035888.XA
Other languages
English (en)
Chinese (zh)
Inventor
克劳迪亚·奥雷利亚纳-塔夫拉
奈杰尔·斯莱特
大卫·法伦-希门尼斯
米歇尔·特普兰斯基
艾玛·巴克斯特
托马斯·贝内特
安东尼·奇塔姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Publication of CN107771084A publication Critical patent/CN107771084A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/003—Compounds containing elements of Groups 4 or 14 of the Periodic Table without C-Metal linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/94—Bismuth compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201680035888.XA 2015-06-24 2016-06-24 非晶金属‑有机框架 Pending CN107771084A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1511125.5 2015-06-24
GBGB1511125.5A GB201511125D0 (en) 2015-06-24 2015-06-24 Amorhous metal-organic frameworks
PCT/EP2016/064746 WO2016207397A1 (en) 2015-06-24 2016-06-24 Amorphous metal-organic frameworks

Publications (1)

Publication Number Publication Date
CN107771084A true CN107771084A (zh) 2018-03-06

Family

ID=53784456

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680035888.XA Pending CN107771084A (zh) 2015-06-24 2016-06-24 非晶金属‑有机框架

Country Status (6)

Country Link
US (1) US11083795B2 (enExample)
EP (1) EP3313856A1 (enExample)
JP (1) JP6904909B2 (enExample)
CN (1) CN107771084A (enExample)
GB (1) GB201511125D0 (enExample)
WO (1) WO2016207397A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115023610A (zh) * 2019-11-28 2022-09-06 剑桥实业有限公司 新型接头化合物
CN119371711A (zh) * 2024-10-30 2025-01-28 江南大学 一种非晶共轭配位聚合物气凝胶材料及其制备方法与应用

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017120111A1 (en) 2016-01-05 2017-07-13 Panaceanano, Inc. Method of preparing cyclodextrin complexes
US10583147B2 (en) * 2016-03-24 2020-03-10 Panaceanano, Inc. Compositions containing cyclodextrin-based metal organic frameworks
WO2018044874A1 (en) * 2016-08-29 2018-03-08 Cornell University Metal organic frameworks and methods of making and using same
GB201717975D0 (en) * 2017-10-31 2017-12-13 Cambridge Entpr Ltd Metal organic framework-based compositions and uses thereof
CN108456241A (zh) * 2018-01-17 2018-08-28 南开大学 多孔框架材料用于生物制品的储运和制备
US11666637B2 (en) 2018-03-09 2023-06-06 Northwestern University Insulin-loaded metal-organic frameworks
KR102125431B1 (ko) * 2018-10-12 2020-06-23 한국과학기술연구원 크기가 조절된 UiO-66의 제조방법 및 이에 따라 제조된 활성이 향상된 화학작용제 가수분해 촉매
US20210386055A1 (en) * 2018-10-30 2021-12-16 Unm Rainforest Innovations Metal-organic Framework-Assisted Cryopreservation of Red Blood-Cells
WO2021035010A1 (en) * 2019-08-20 2021-02-25 Shengqian Ma Corrole-based frameworks and methods of use thereof
KR102253318B1 (ko) * 2020-06-02 2021-05-18 (주)위바이오트리 금속 상 변환 화합물 및 이의 제조 방법
CN112500581B (zh) * 2020-12-08 2022-01-28 广西民族师范学院 一种基于1,3,5-三(甲氧基羧基)苯构筑的镍金属配位聚合物及其合成方法
EP4011365A1 (en) 2020-12-09 2022-06-15 Cambridge Enterprise, Ltd. Mof nanoparticles
CN113398956B (zh) * 2021-06-17 2023-08-04 西安石油大学 一种可见光响应的BiOI光催化剂及其制备方法和应用
CN113791058B (zh) * 2021-09-15 2022-09-23 南京大学 一种利用lmof组成的传感器阵列检测抗生素的方法
CN114657600B (zh) * 2022-04-25 2023-05-19 江西师范大学 一种3D微米花复合材料Fe-CoP@C及其制备方法和应用
US20250351820A1 (en) * 2022-06-06 2025-11-20 Kansas State University Research Foundation Supramolecular porous organic frameworks for storage and delivery of volatile guests
CN115785468A (zh) * 2022-11-21 2023-03-14 苏州大学 一种用于富集细胞外囊泡的zif-8-dspe材料及其制备方法和应用
CN116584480B (zh) * 2023-04-26 2025-05-23 南京大学 金属有机框架纳米农药控释剂的制备方法及其应用
CN118437299A (zh) * 2024-06-06 2024-08-06 中国科学院青海盐湖研究所 铬基MOFs吸附剂及其制备方法、铬基MOFs吸附剂的应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6024789B2 (ja) * 1976-09-03 1985-06-14 小野薬品工業株式会社 ５−フルオロウラシル誘導体化合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115023610A (zh) * 2019-11-28 2022-09-06 剑桥实业有限公司 新型接头化合物
CN119371711A (zh) * 2024-10-30 2025-01-28 江南大学 一种非晶共轭配位聚合物气凝胶材料及其制备方法与应用

Also Published As

Publication number Publication date
US11083795B2 (en) 2021-08-10
GB201511125D0 (en) 2015-08-05
WO2016207397A1 (en) 2016-12-29
EP3313856A1 (en) 2018-05-02
JP6904909B2 (ja) 2021-07-21
US20180147284A1 (en) 2018-05-31
JP2018522860A (ja) 2018-08-16

Similar Documents

Publication Publication Date Title
JP6904909B2 (ja) 非晶質の金属有機構造体
Orellana-Tavra et al. Amorphous metal–organic frameworks for drug delivery
Song et al. An oral drug delivery system with programmed drug release and imaging properties for orthotopic colon cancer therapy
Orellana-Tavra et al. Drug delivery and controlled release from biocompatible metal–organic frameworks using mechanical amorphization
Li et al. Composite CD-MOF nanocrystals-containing microspheres for sustained drug delivery
Arruebo et al. Development of magnetic nanostructured silica-based materials as potential vectors for drug-delivery applications
Li et al. Polyoxometallates trapped in a zeolitic imidazolate framework leading to high uptake and selectivity of bioactive molecules
EP2260048B1 (fr) Solide hybride cristallin poreux pour l'adsorption et la liberation de gaz a interet biologique
Wu et al. Functional mesoporous bioactive glass nanospheres: synthesis, high loading efficiency, controllable delivery of doxorubicin and inhibitory effect on bone cancer cells
Lawson et al. Optimizing ibuprofen concentration for rapid pharmacokinetics on biocompatible zinc-based MOF-74 and UTSA-74
Tamames‐Tabar et al. MOFs in pharmaceutical technology
EP3485886A1 (en) Oral pharmaceutical composition of tecovirimat and preparation method therefor
Mohamed et al. Studies on preparation and evaluation of soluble 1: 1 stoichiometric curcumin complex for colorectal cancer treatment
Du et al. A three-dimensional Nd (III)-based metal–organic framework as a smart drug carrier
Vodyashkin et al. Synthesis and activation of pH-sensitive metal–organic framework Sr (BDC)∞ for oral drug delivery
KR20210020228A (ko) 프러시안 블루 나노케이지 및 목적물질을 포함하는 전달체
EP3843705A1 (en) Preparation of nanosuspension comprising nanocrystals of active pharmaceutical ingredients with little or no stabilizing agents
Bhattacharjee et al. CeO2 nanoparticles incorporated MIL-100 (Fe) composites for loading of an anticancer drug: effects of HF in composite synthesis and drug loading capacity
Wang et al. IRMOF‐8‐encapsulated curcumin as a biocompatible, sustained‐release nano‐preparation
Pham et al. Nanoscale ZIF-8 as an efficient carboplatin carrier for targeted cancer therapy
Ahmed et al. NUIG4: A biocompatible pcu metal–organic framework with an exceptional doxorubicin encapsulation capacity
WO2012026896A1 (en) Surface modified micronized tacrolimus crystalline particles and pharmaceutical compositions thereof
Namazi et al. Facile synthesis and characterization of ibuprofen-mesoporous hydroxyapatite nanohybrid as a sustained drug delivery system
CN101945671A (zh) 用于水溶性阳离子两亲性的药用活性物质给药的药物递送系统
KR20220000850A (ko) 비타민 b1의 보호 및 전달을 위한 장용성 조성물

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20180306